| Name | Title | Contact Details |
|---|
We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.
Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.
Lyophilization Services of New England is a Bedford, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Solugen is a venture-backed biotech startup that replaces petroleum based products with plant-derived substitutes.
Orion Genomics is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.